Previous 10 |
home / stock / dsnky / dsnky news
MUNICH , March 18, 2019 /PRNewswire/ -- ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice Late-breaking data presented at EHRA 2019, the annual ...
The FDA has accepted under Priority Review Daiichi Sankyo's ( OTCPK:DSNKY ) marketing application seeking approval for pexidartinib for the treatment of adult patients with a rare cancer called symptomatic tenosynovial giant cell tumor (TGCT), a non-malignant cancer of the joint or tendon ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...